INNOVATE Announces Closing of the Sale of a Controlling Interest in its Broadcasting Segment to CONX
Globe Newswire (Wed, 2-Sep 8:30 AM ET)
MediBeacon Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology
Globe Newswire (Tue, 18-Aug 8:00 AM ET)
IES Holdings to Acquire DBM Global
Globe Newswire (Mon, 10-Aug 8:00 AM ET)
INNOVATE Agrees to $650 Million Sale of DBM Global to IES Holdings
Globe Newswire (Mon, 10-Aug 8:00 AM ET)
INNOVATE Corp. Delivers Record Infrastructure Results and Significant Profit Turnaround in Q2 2026
Market Chameleon (Fri, 7-Aug 6:29 AM ET)
Market Chameleon (Fri, 7-Aug 3:05 AM ET)
INNOVATE Corp. Announces Second Quarter 2026 Results
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
INNOVATE Corp. to Report Second Quarter 2026 Results on August 6th
Globe Newswire (Mon, 3-Aug 4:05 PM ET)
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
Innovate Corp. trades on the NYSE stock market under the symbol VATE.
As of September 23, 2026, VATE stock price declined to $7.68 with 108,233 million shares trading.
VATE has a beta of 2.66, meaning it tends to be more sensitive to market movements. VATE has a correlation of 0.06 to the broad based SPY ETF.
VATE has a market cap of $104.87 million. This is considered a Micro Cap stock.
In the last 3 years, VATE traded as high as $21.30 and as low as $3.25.
The top ETF exchange traded funds that VATE belongs to (by Net Assets): VTI, VXF, VTWO, BUSM, VTWG.
VATE has outperformed the market in the last year with a price return of +145.7% while the SPY ETF gained +16.9%. However, in the short term, VATE had mixed performance relative to the market. It has underperformed in the last 3 months, returning -57.7% vs +4.9% return in SPY. But in the last 2 weeks, VATE shares have fared better than the market returning +13.1% compared to SPY +1.0%.
VATE support price is $7.80 and resistance is $8.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VATE shares will trade within this expected range on the day.